UNSPSC 51142039: Ethoheptazine citrate

This classification denotes an opioid receptor agonist with the molecular formula C16H23NO2.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LXK8EE245D, chemically known as ethyl hexahydro-1-methyl-4-phenyl-1h-azepine-4-carboxylate, compound with citric acid (1:1) but more generally known as ethoheptazine citrate, which bears US NIH Compound Identifier 23165. European Medicines Agency schedules Ethoheptazine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02001MIG.

UNSPSC 51142039 Ethoheptazine citrate is a Commodity code with minimal recent state and local procurement activity directly aligned to this specific pharmaceutical ingredient. The three recent opportunities tagged to this code—a county naloxone and drug deactivation systems purchase, a state health commission RFI on direct-to-manufacturer prescriptions, and a multistate cooperative purchasing RFP for generic pharmaceuticals and OTC products—represent broader pharmaceutical procurement at the state, county, and cooperative levels rather than solicitations specifically for ethoheptazine citrate itself. The code's nominal scope (a synthetic opioid analgesic agent) does not match the concrete work being solicited in these opportunities, which focus on naloxone (an opioid antagonist), direct pharmacy contracting models, and generic multi-source pharmaceuticals as product categories rather than named active pharmaceutical ingredients.

The issuing bodies span county health departments, state health and human services commissions, and multistate cooperative purchasing organizations. Seminole County, Florida posted an IFB on June 30, 2026, for naloxone and drug deactivation systems with a response deadline of July 26, 2023 (note: date discrepancy in source); the Texas Health and Human Services Commission issued an RFI on April 3, 2026, exploring direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026, serving participating state and local government facilities across Minnesota and Oregon. The code shows little decision-relevant recent activity for firms pursuing ethoheptazine citrate specifically; opportunities are tagged to this code but do not solicit it by name or as a primary product line.